Launched in Malaysia for the kapchai segment is 2025 Modenas Kriss 125 Fi, priced at RM5,620. Pricing does not include road tax, insurance or registration and there are two colour options ...

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

Ratings for Moderna MRNA were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...

Cafe Kestrel in Brooklyn and Cocina Consuelo in Harlem can restore the spirit with warm service, cheery surroundings and deeply satisfying food. Cafe Kestrel is an unassuming charmer in Red Hook ...

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...